Glycolithocholic acid increases the frequency of circulating Tregs through constitutive androstane receptor to alleviate postmenopausal osteoporosis.

BAs Gut microbiota Immune cell subsets PMO SCFAs

Journal

Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032

Informations de publication

Date de publication:
29 Nov 2023
Historique:
received: 05 09 2023
revised: 23 11 2023
accepted: 27 11 2023
pubmed: 1 12 2023
medline: 1 12 2023
entrez: 30 11 2023
Statut: aheadofprint

Résumé

Gut microbiota and their metabolic activity are important regulators of host immunity. However, the role of gut microbiota and their metabolic activity-mediated osteoimmunity in postmenopausal osteoporosis (PMO) remains unknown. This study aimed to explore the role of gut microbiota and their metabolic activity in PMO. 16S rDNA sequencing was used for analyzing the gut microbiota diversity of patients with PMO and rat models, and a targeted metabolism study was performed for analyzing metabolite levels. Flow cytometry was used for analyzing the frequency of immune cells. Micro-CT was used for analyzing bone damage in rat models. Fecal microbiota transplantation was performed for exploring the therapeutic effect of the gut microbiota on PMO. CD4 Patients with PMO exhibited reduced gut microbiota diversity, and fecal glycolithocholic acid (GLCA) levels correlated with the degree of osteoporosis. GLCA levels in the gut were positively correlated with the frequency of circulating Tregs in ovariectomized rats. Restoration of the gut microbiota alleviated osteoporosis in ovariectomized rats. Circulating GLCA augmented CD4 GLCA alleviated PMO by increasing the frequency of circulating Tregs, acting via the constitutive androstane receptor. This study reveals a new strategy for the treatment of PMO, with GLCA as a potential drug candidate.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
Gut microbiota and their metabolic activity are important regulators of host immunity. However, the role of gut microbiota and their metabolic activity-mediated osteoimmunity in postmenopausal osteoporosis (PMO) remains unknown. This study aimed to explore the role of gut microbiota and their metabolic activity in PMO.
EXPERIMENTAL APPROACH METHODS
16S rDNA sequencing was used for analyzing the gut microbiota diversity of patients with PMO and rat models, and a targeted metabolism study was performed for analyzing metabolite levels. Flow cytometry was used for analyzing the frequency of immune cells. Micro-CT was used for analyzing bone damage in rat models. Fecal microbiota transplantation was performed for exploring the therapeutic effect of the gut microbiota on PMO. CD4
KEY RESULTS RESULTS
Patients with PMO exhibited reduced gut microbiota diversity, and fecal glycolithocholic acid (GLCA) levels correlated with the degree of osteoporosis. GLCA levels in the gut were positively correlated with the frequency of circulating Tregs in ovariectomized rats. Restoration of the gut microbiota alleviated osteoporosis in ovariectomized rats. Circulating GLCA augmented CD4
CONCLUSION AND IMPLICATIONS CONCLUSIONS
GLCA alleviated PMO by increasing the frequency of circulating Tregs, acting via the constitutive androstane receptor. This study reveals a new strategy for the treatment of PMO, with GLCA as a potential drug candidate.

Identifiants

pubmed: 38036190
pii: S0006-2952(23)00544-0
doi: 10.1016/j.bcp.2023.115951
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115951

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Xiaoyu Cai (X)

Department of Pharmacy, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China. Electronic address: cxyahmu@126.com.

Zhi Li (Z)

Department of Gynaecology and Obstetrics, Women's Hospital School of Medicine Zhejiang University, Hangzhou 310006, China.

Yao Yao (Y)

Department of Pharmacy, Women's Hospital School of Medicine Zhejiang University, Hangzhou 310006, China.

Yongquan Zheng (Y)

Department of Pharmacy, Women's Hospital School of Medicine Zhejiang University, Hangzhou 310006, China.

Meng Zhang (M)

Department of Pharmacy, Women's Hospital School of Medicine Zhejiang University, Hangzhou 310006, China.

Yiqing Ye (Y)

Department of Pharmacy, Women's Hospital School of Medicine Zhejiang University, Hangzhou 310006, China.

Classifications MeSH